Literature DB >> 22186792

Self-complementary AAVs induce more potent transgene product-specific immune responses compared to a single-stranded genome.

TeLang Wu1, Katrin Töpfer, Shih-Wen Lin, Hua Li, Ang Bian, Xiang Y Zhou, Katherine A High, Hildegund C J Ertl.   

Abstract

Using a mouse model we show that self-complementary (sc) adeno-associated virus (AAV) vectors pseudotyped with capsids of serotypes 2, 7 or 8 induce more potent transgene product-specific CD8(+) T cell and antibody responses compared to corresponding single-stranded (ss)AAV vectors. These data suggest that the higher and more rapidly appearing amounts of transgene product achieved with scAAV vectors may increase detrimental immune responses in gene transfer recipients.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22186792      PMCID： PMC3293612          DOI： 10.1038/mt.2011.280

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


  29 in total

1.  Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model.

Authors:  B Wang; J Li; X Xiao
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

Review 2.  New recombinant serotypes of AAV vectors.

Authors:  Guangping Gao; Luk H Vandenberghe; James M Wilson
Journal:  Curr Gene Ther       Date:  2005-06       Impact factor: 4.391

3.  Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity.

Authors:  Joseph E Rabinowitz; Fabienne Rolling; Chengwen Li; Hervè Conrath; Weidong Xiao; Xiao Xiao; R Jude Samulski
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver.

Authors:  Ashley T Martino; Masataka Suzuki; David M Markusic; Irene Zolotukhin; Renee C Ryals; Babak Moghimi; Hildegund C J Ertl; Daniel A Muruve; Brendan Lee; Roland W Herzog
Journal:  Blood       Date:  2011-04-07       Impact factor: 22.113

5.  A simple method for improved assay demonstrates that HIV p24 antigen is present as immune complexes in most sera from HIV-infected individuals.

Authors:  P Nishanian; K R Huskins; S Stehn; R Detels; J L Fahey
Journal:  J Infect Dis       Date:  1990-07       Impact factor: 5.226

6.  Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment.

Authors:  E John Wherry; Joseph N Blattman; Kaja Murali-Krishna; Robbert van der Most; Rafi Ahmed
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

7.  Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II.

Authors:  Baodong Sun; Haoyue Zhang; Luis M Franco; Sarah P Young; Ayn Schneider; Andrew Bird; Andrea Amalfitano; Y-T Chen; Dwight D Koeberl
Journal:  Mol Ther       Date:  2005-01       Impact factor: 11.454

8.  Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors.

Authors:  Anne-Kathrin Zaiss; Qiang Liu; Gloria P Bowen; Norman C W Wong; Jeffrey S Bartlett; Daniel A Muruve
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

9.  An experimental vaccine expressing wild-type p53 induces protective immunity against glioblastoma cells with high levels of endogenous p53.

Authors:  M Blaszczyk-Thurin; I O Ertl; H C J Ertl
Journal:  Scand J Immunol       Date:  2002-10       Impact factor: 3.487

10.  Characterization of tissue tropism determinants of adeno-associated virus type 1.

Authors:  Bernd Hauck; Weidong Xiao
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103
View more
  25 in total

Review 1.  Liver induced transgene tolerance with AAV vectors.

Authors:  Geoffrey D Keeler; David M Markusic; Brad E Hoffman
Journal:  Cell Immunol       Date:  2017-12-05       Impact factor: 4.868

Review 2.  Complexity of immune responses to AAV transgene products - Example of factor IX.

Authors:  Roland W Herzog
Journal:  Cell Immunol       Date:  2017-05-29       Impact factor: 4.868

3.  Unique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene Transfer.

Authors:  Geoffrey L Rogers; Masataka Suzuki; Irene Zolotukhin; David M Markusic; Laurence M Morel; Brendan Lee; Hildegund C J Ertl; Roland W Herzog
Journal:  J Innate Immun       Date:  2015-01-20       Impact factor: 7.349

4.  Fetal Gene Therapy Using a Single Injection of Recombinant AAV9 Rescued SMA Phenotype in Mice.

Authors:  Afrooz Rashnonejad; Gholamhossein Amini Chermahini; Cumhur Gündüz; Hüseyin Onay; Ayça Aykut; Burak Durmaz; Meral Baka; Qin Su; Guangping Gao; Ferda Özkınay
Journal:  Mol Ther       Date:  2019-08-31       Impact factor: 11.454

Review 5.  Immune responses to AAV vectors: overcoming barriers to successful gene therapy.

Authors:  Federico Mingozzi; Katherine A High
Journal:  Blood       Date:  2013-04-17       Impact factor: 22.113

6.  CpG-depleted adeno-associated virus vectors evade immune detection.

Authors:  Susan M Faust; Peter Bell; Benjamin J Cutler; Scott N Ashley; Yanqing Zhu; Joseph E Rabinowitz; James M Wilson
Journal:  J Clin Invest       Date:  2013-06-17       Impact factor: 14.808

7.  Prevention of Lethal Murine Hypophosphatasia by Neonatal Ex Vivo Gene Therapy Using Lentivirally Transduced Bone Marrow Cells.

Authors:  Osamu Iijima; Koichi Miyake; Atsushi Watanabe; Noriko Miyake; Tsutomu Igarashi; Chizu Kanokoda; Aki Nakamura-Takahashi; Hideaki Kinoshita; Taku Noguchi; Shinichi Abe; Sonoko Narisawa; José Luis Millán; Takashi Okada; Takashi Shimada
Journal:  Hum Gene Ther       Date:  2015-11-19       Impact factor: 5.695

Review 8.  Gene therapy for hemophilia.

Authors:  Geoffrey L Rogers; Roland W Herzog
Journal:  Front Biosci (Landmark Ed)       Date:  2015-01-01

Review 9.  Overcoming innate immune barriers that impede AAV gene therapy vectors.

Authors:  Manish Muhuri; Yukiko Maeda; Hong Ma; Sanjay Ram; Katherine A Fitzgerald; Phillip Wl Tai; Guangping Gao
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

Review 10.  Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?

Authors:  Wei Zhan; Manish Muhuri; Phillip W L Tai; Guangping Gao
Journal:  Front Immunol       Date:  2021-05-11       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.